Cevimeline Hydrochloride
The hydrochloride salt formulation of cevimeline provides the same muscarinic agonist activity as the parent compound, used for xerostomia in Sjögren's syndrome. It should be used cautiously in patients with asthma, narrow-angle glaucoma, or cardiovascular disease, as cholinergic stimulation may worsen these conditions. Adequate fluid intake is recommended to maximize its salivary stimulant benefit.
分子量
489.6000 g/mol
TPSA
76.50 Ų
作用機序
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
2D構造
Cite this structure
Embed this structure
SMILES
CC1OC2(CS1)CN1CCC2CC1.Cl.O
InChI
InChI=1S/C10H17NOS.ClH.H2O/c1-8-12-10(7-13-8)6-11-4-2-9(10)3-5-11;;/h8-9H,2-7H2,1H3;1H;1H2
Molecular Formula
C20H38Cl2N2O3S2
HBD / HBA
3 / 7
回転可能結合数
0
重原子数
29
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
よくある質問
The hydrochloride salt formulation of cevimeline provides the same muscarinic agonist activity as the parent compound, used for xerostomia in Sjögren's syndrome. It should be used cautiously in patients with asthma, narrow-angle glaucoma, or cardiovascular disease, as cholinergic stimulation may worsen these conditions. Adequate fluid intake is recommended to maximize its salivary stimulant benefit.
Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.
Yes, Cevimeline Hydrochloride is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2218917. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 73416227. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="cevimeline-hydrochloride"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/cevimeline-hydrochloride/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/cevimeline-hydrochloride/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/cevimeline-hydrochloride/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="cevimeline-hydrochloride"></drugfyi-drug>